# WeDo Capital Management

> WeDo Capital Management is a VC fund in Beijing backing Biotechnology and Medical. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 13
- Last investment: Jul 2023
- Lead investor: 23%
- Last updated: Aug 2026

WeDo Capital Management is a Beijing-based venture capital and investment firm focused on healthcare and technology. It began operation on February 2, 2016, with its headquarters in Beijing in China

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 38% |
| Medical | 4 | 31% |
| Health Care | 3 | 23% |
| Therapeutics | 2 | 15% |
| Pharmaceutical | 2 | 15% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 46% |
| Series B | 3 | 23% |
| Seed | 1 | 8% |
| Angel | 1 | 8% |
| Series C | 1 | 8% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 10 | 77% |
| United States | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Next Generation Gene Therapeutics | Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world.NGGT was founded in March 2020by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products. | $40M | Series B | Jul 11, 2023 |  |
| Drug Farm | Drug Farm is a China and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. | $27M | Series C | May 16, 2023 |  |
| Iridium Molybdenum Intelligent | Iridium Molybdenum Intelligent engages in creating intelligent construction machinery products and providing integrated solutions for mine capacity services. | $16M | Series A | Mar 22, 2023 |  |
| Qihui Biotechnology | Qihui Biotechnology is a research and development company of testing and diagnostic equipment. |  | Series A | Dec 06, 2022 |  |
| HemaCell | Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish aplatform using platelet cells as a drug delivery carrier. |  | Series A | May 27, 2022 |  |
| Doctor AI Yisheng Intelligence | Doctor AI is a med-tech firm that provides a smart AI medical record quality control system. |  | Series A | Dec 28, 2021 |  |
| Geneus | Geneus is a developer of gene sequencers and reagents. |  | Series B | Sep 28, 2021 |  |
| Chinagene Tech | Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical geneticdiagnosis services for hereditary ophthalmology patients. |  | Seed | Jun 01, 2021 |  |
| BridGene Biosciences | BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets. | $12M | Series A | May 05, 2021 |  |
| Next Generation Gene Therapeutics | Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world.NGGT was founded in March 2020by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products. | $30M | Series A | Apr 22, 2021 |  |

10 of 13 investments shown.

## Co-investors
- [Wedo Venture Partners](https://shizune.co/investors/profile/wedo-vc) — VC Fund, 10 deals together
- [Northern Light Venture Capital](https://shizune.co/investors/profile/northern-light-venture-capital) — VC Fund, 3 deals together
- [DT Capital Partners](https://shizune.co/investors/profile/dt-capital-partners) — VC Fund, 2 deals together
- [Shanghai Biomedical Industrial Equity Investment Fund](https://shizune.co/investors/profile/shanghai-biomedical-industrial-equity-investment-fund) — VC Fund, 2 deals together
- [Betta Capital](https://shizune.co/investors/profile/betta-capital) — VC Fund, 1 deal together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Brick & Mortar Ventures](https://shizune.co/investors/profile/brick-mortar-vc) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Foundamental](https://shizune.co/investors/profile/foundamental) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [East Ventures](https://shizune.co/investors/profile/east-ventures) — VC Fund
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund

## Featured in investor lists
- [Construction VC Funds in China](https://shizune.co/investors/construction-vc-funds-china)
- [Construction Investors in Asia](https://shizune.co/investors/construction-investors-asia)
- [Construction VC Funds in Asia](https://shizune.co/investors/construction-vc-funds-asia)

## FAQ

### What does WeDo Capital Management invest in?

WeDo Capital Management invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did WeDo Capital Management last invest?

The most recent investment recorded for WeDo Capital Management closed in Jul 2023. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co